Certara client forums in China, Korea, and Japan support collaboration and networking among drug developers using model-informed drug development approaches to bring new treatments to patients faster.
RADNOR, PA – SEPTEMBER 3, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it is expanding its premier client event, Certainty, hosting one-day conferences in China, South Korea, and Japan throughout September.
Ripe for innovation and growth, the APAC region continues to solidify as an epicenter for drug discovery and development. In 2023, the revenue of the pharmaceutical market in the region was $210 billion. Certara understands that innovation is driven by collaboration. At Certainty, attendees gain access to thought industry leaders across biosimulation, data and analytics, and regulatory science.
“Our industry relies on bringing together multi-disciplinary leaders across drug development to solve challenging problems with innovative solutions,” said William F. Feehery, CEO of Certara. “We launched the Certainty program to share our comprehensive vision for transforming drug development along with knowledge and experiences from our client community. We look forward to welcoming hundreds of leaders across the drug development industry in APAC in September.”
Certainty events are designed for pharmacometricians, clinical pharmacologists, regulatory science professionals, biostatisticians, and data scientists. Certainty APAC will explore the latest trends in biosimulation, drug development, generative AI solutions for regulatory writing, and more. The events are currently fully subscribed. Featured sessions from Certara experts include:
- Biosimulation at scale: Industrializing quantitative systems pharmacology to guide drug-development decision-making
by John M. Burke, PhD, VP, Global Head of ABM Scientific Affairs, Certara - How PBPK Help Accelerate Your Drug Development – Case Studies
by Noriko Okudaira, PhD, Sr Director of PBPK Consultancy
- The Era of Generative AI: Revolutionizing Regulatory Writing
by Heeyoung Kim, Manager of Solution Consultant, - FDA Project Optimus and MIDD Case Studies: Road to Approval and Beyond
by Mayumi Hasegawa PhD, Sr. Consultant, Drug Development Solutions, Moving from Hype to Reality in Pharmaceutical AI Applications
by Sean McGee, Director of Product
- When: Thursday, September 5, 2024, from 9 am to 5 pm
- Where: Crowne Plaza Shanghai Jinxiu
- Guest speakers:
- Yue Wu, PhD, DMPK Director, Beigene
- Huafang Jiang, Senior Director of Analysis and Bioanalysis, Joinn
- Yi Lin, PhD, Head of AI Data and Digital, Roche
- Hongyun Wang, PhD, Professor, Vice Director, Peking Union Medical College Hospital
- Liu Li, PhD, Professor, China Pharmaceutical University
- Hao Jiang, PhD, Assistant Director, Hengrui
- Victor Wu, PhD, CEO, Data Science Express
- When: Tuesday, September 10, 2024, from 9 am to 5 pm
- Where: GRAVITY SEOUL PANGYO
- Guest speakers:
- Jae-Gook Shin, CEO, SPMED, Inje University
- Hailin Zhao, Chief Development Officer, Eyegene
- Seungjae Baek, GID Partners
- Boyoung Jeong, Sr, Director, MedClaris
- When: Thursday, September 12, 2024, from 10 am to 4 pm
- Where: TKP Garden City PREMIUM Shinagawa Takanawa
- Guest speakers:
- Shintaro Nakayama, PhD, Daiichi Sankyo
- Kenji Shimuzu, Nobelpharma
- Shinji Kobuchi PhD, Kyoto Pharmaceutical University
- Tak Yamada, NVIDIA
For more information about Certara’s fall event schedule, including future global Certainty events and conferences, please visit: https://www.certara.com/resources/?categories=live-events
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,300 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Visit us at www.certara.com.
Certara Contact:
Sheila Rocchio
sheila.rocchio@certara.com
Media Contact:
Alyssa Horowitz
PAN
certara@pancomm.com